title: Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
authors.affiliation: Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, Leuven, Belgium.
authors.forename: Iris
authors.initials: I
authors.lastname: Detrez
authors.affiliation: Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, Leuven, Belgium ann.gils@pharm.kuleuven.be.
authors.forename: Ann
authors.initials: A
authors.lastname: Gils
mesh_terms: D006801:Humans; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D017326:Clinical Trials, Phase III as Topic; D017322:Clinical Trials, Phase II as Topic
chemical_list: D000911:Antibodies, Monoclonal; C529000:golimumab; D014409:Tumor Necrosis Factor-alpha